Delving into the Latest Updates on Morphine Sulfate with Synapse

Overview

Basic Info

SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously.

Drug Type

Small molecule drug

Synonyms

Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066

+ [36]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Acute PainCancer PainPain+ [1]

Inactive Indication

AnesthesiaArthralgiaHallux Valgus+ [8]

Originator Organization

Hikma Pharmaceuticals USA, Inc.

Active Organization

Hikma Pharmaceuticals USA, Inc.

Teikoku Seiyaku Co. Ltd.Shionogi Pharma Co., Ltd.

+ [8]

Inactive Organization

Pfizer Inc.

Javelin Pharmaceuticals, Inc.

Hebei Aoxing Group Pharmaceutical Co. Ltd.

+ [9]

License Organization

Inspirion Delivery Sciences LLC

Daiichi Sankyo, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (18 Sep 1984),

Chronic Pain

RegulationFast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC34H40N2O10S

InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N

CAS Registry64-31-3

The goal of this clinical trial is to learn if using calcium sulfate beads that contain vancomycin (an antibiotic) and pain-relieving medicines during spine surgery can improve recovery compared to standard care with intravenous (IV) morphine and local pain medicines.
Researchers want to know if the sustained release formulation of morphine from these calcium sulfate beads affect:
* Postoperative length of stay
* Postoperative pain scores
* Postoperative narcotic analgesic requirements
All participants in this study will already be scheduled to have spine surgery as part of their regular medical care. During surgery, participants will be assigned to receive either intraoperative placement of calcium sulfate beads with vancomycin alone or vancomycin with morphine and bupivacaine. All patients will still have access to standard of care with IV and PO pain regimens. Participants will then be followed after surgery to measure their pain, recovery, and medication use.
Participation is voluntary, and choosing not to join will not affect a person's medical care.

Start Date01 Jan 2026

Sponsor / Collaborator

The Massachusetts General Hospital

ChiCTR2500112547

/ Not yet recruitingNot Applicable

The effect of low-dose esketamine on intrathecal morphine induced-pruritus during cesarean section

Start Date30 Dec 2025

Sponsor / Collaborator-

NCT07231926

/ Not yet recruitingNot ApplicableIIT

The Effects of Intrathecal Morphine in Addition to Serratus Anterior Plane Block and Dexmedetomidine on Postoperative Recovery (QoR-15) and Systemic Inflammation in Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial

This study will compare two different methods of pain management in patients undergoing video-assisted thoracoscopic surgery (VATS). One group will receive a combination of spinal morphine, nerve block, and dexmedetomidine, while the other group will receive a nerve block and dexmedetomidine without spinal morphine. All patients will receive standard pain medications after surgery. The purpose is to see if adding spinal morphine improves pain control and recovery after surgery.

Start Date01 Dec 2025

Sponsor / Collaborator

Ataturk University

100 Clinical Results associated with Morphine Sulfate

Login to view more data

100 Translational Medicine associated with Morphine Sulfate

Login to view more data

100 Patents (Medical) associated with Morphine Sulfate

Login to view more data

34,568

Literatures (Medical) associated with Morphine Sulfate

31 Dec 2025·Gut Microbes

Gut dysbiosis was inevitable, but tolerance was not: temporal responses of the murine microbiota that maintain its capacity for butyrate production correlate with sustained antinociception to chronic morphine

Article

Author: Calawa, Jennifer ; Rosa, Zachary ; Whistler, Jennifer L. ; Whistler, Cheryl A. ; Felth, Lindsey ; Pavlik, Nadia ; Foxall, Randi ; Maret, Soren ; Sall, Izabella ; Gaur, Anirudh

The therapeutic benefits of opioids are compromised by the development of analgesic tolerance, which necessitates higher dosing for pain management thereby increasing the liability for drug dependence and addiction. Rodent models indicate opposing roles of the gut microbiota in tolerance: morphine-induced gut dysbiosis exacerbates tolerance, whereas probiotics ameliorate tolerance. Not all individuals develop tolerance, which could be influenced by differences in microbiota, and yet no study design has capitalized upon this natural variation. We leveraged natural behavioral variation in a murine model of voluntary oral morphine self-administration to elucidate the mechanisms by which microbiota influences tolerance. Although all mice shared similar morphine-driven microbiota changes that largely masked informative associations with variability in tolerance, our high-resolution temporal analyses revealed a divergence in the progression of dysbiosis that best explained sustained antinociception. Mice that did not develop tolerance maintained a higher capacity for production of the short-chain fatty acid (SCFA) butyrate known to bolster intestinal barriers and promote neuronal homeostasis. Both fecal microbial transplantation (FMT) from donor mice that did not develop tolerance and dietary butyrate supplementation significantly reduced the development of tolerance independently of suppression of systemic inflammation. These findings could inform immediate therapies to extend the analgesic efficacy of opioids.

01 Dec 2025·JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY

Synthesis of a green smart nano-carrier encapsulating Allium jesdianum extract for superior corrosion protection in saline environment using natural polymers

Author: Zargar, Behrooz ; Kahkesh, Homa

This study aims to develop a hybrid corrosion inhibitive system based on employing soy protein isolate/chitosan (SPI/CS) complex nanoparticle as a novel and green smart carrier for active protection of mild steel in 3.5 wt% NaCl solutionFor this purpose, the SPI/CS nanocarrier was synthesized and impregnated with aqueous extract of Allium jesdianum (AEAJ= as a green corrosion inhibitor to obtain SPI/CS@AEAJ.The prepared SPI/CS@AEAJ nanoparticles were characterized by various anal. methods, such as FT-IR and SEM.Active corrosion inhibition of the designed system was explored by electrochem. techniques.Results demonstrated the successful loading of AEAJ compounds in the polymeric matrix and the pH-dependent behavior of inhibitor mols. released from SPI/CS@AEAJ.The outcomes of electrochem. impedance spectroscopy (EIS) and polarization measurements manifested significant inhibition performance of about 93.57 % for the hybrid system.Accordingly, the total corrosion resistance increased from 1172 Ω.cm² for the Blank sample to 18255 Ω.cm² for the sample containing a mixture of SPI/CS/AEAJ and zinc cations after 24 h immersion of steel panels, indicating excellent and long-term corrosion protection of the system.The surface characterization methods proved the deposition of surficial inhibitive film on the steel samples arising from chelate formation between organic inhibitors and Zn²⁺ ions.

03 Oct 2025·The International journal of neuroscience

The effects of combined acupuncture anesthesia and serratus anterior plane block with ropivacaine on postoperative analgesia in patients undergoing chest surgery

Article

Author: Wu, Zhen ; Wang, Jieqiong ; Wang, Chunfeng ; Shi, Lingyan ; Yu, Xiangyuan ; Cai, Hongqin

OBJECTIVE:

To investigate the effects of combined acupuncture anesthesia and ropivacaine on postoperative analgesia and neuro-related factors in patients undergoing chest surgery.

METHODS:

The analgesic drug dosage, postoperative PCIA pressing times, VAS scores at rest and during activity at 6 h (T1), 12 h (T2), 18 h (T3), and 24 h (T4) postoperatively.

RESULTS:

The analgesic drug dosage and postoperative PCIA pressing times were lower in the observation group than in the control group (p < 0.05). The VAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The SAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The levels of IL-6 and IL-10 on postoperative day 1 were higher than those on preoperative day 1 in both groups, with a smaller change in the observation group (p < 0.05). The levels of S100β protein on postoperative day 1 were higher than those on preoperative day 1 in both groups, while the BDNF levels were lower, with a smaller change in the observation group (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control group (11.36%) and the observation group (15.56%) (p > 0.05).

CONCLUSION:

Combined acupuncture anesthesia and ropivacaine can effectively improve postoperative analgesia and agitation in patients undergoing chest surgery, reduce the dosage of analgesic drugs, regulate the levels of inflammatory factors and neurotrophic factors in patients, and do not increase the risk of adverse reactions related to patients.

173

News (Medical) associated with Morphine Sulfate

20 Nov 2025

·www.einpresswire.com

Cytogel Pharma Announces Equity Offering to Advance CYT-1010, A Transformative Pain Solution

CYT-1010 represents a potential turning point in the treatment of moderate to severe pain.” — C. Dean Maglaris, Chairman & CEO DARIEN, CT, UNITED STATES, November 20, 2025 / EINPresswire.com / -- Cytogel Pharma, a clinical-stage biopharmaceutical startup pioneering first-in-class endomorphin-based therapies, announced today that it is progressing its equity financing round to advance development of its lead compound, CYT-1010 ® , into Phase 2 clinical trials. CYT-1010 is the first member of a new class of drugs, the endomorphins, to reach clinical development, representing a transformative approach to relieve pain and overcome the limitations of traditional opioids. CYT-1010 acts through a novel mechanism of action on the truncated form of the mu-opioid receptor (MOR) to deliver potent, targeted pain relief. Unlike classical opioids, CYT-1010 is derived from the endomorphins, which are naturally produced in the human brain. They preferentially activate the truncated MORs in the central nervous system that block pain while avoiding the unwanted adverse effects such as respiratory depression and addiction potential. Following a successful Phase 1 clinical trial demonstrating safety and analgesic activity in humans, Cytogel is preparing to initiate Phase 2 clinical development. Research has shown that CYT-1010 provides three-to-four times more potent pain relief than morphine, along with strong anti-inflammatory benefits, substantially reduced abuse potential, and profoundly reduced respiratory depression. “CYT-1010 represents a potential turning point in the treatment of moderate to severe pain,” said C. Dean Maglaris , Chairman and Chief Executive Officer of Cytogel Pharma. “Our goal has always been to create a medicine that provides safe, effective pain relief without the devastating side effects associated with traditional opioids. With strong scientific validation, a clear path into Phase 2, and the continued confidence of our investors and board, we are well-positioned to deliver on that vision.” In breakthrough preclinical research, an analog of CYT-1010 demonstrated anti-inflammatory effects, reducing recovery time by 50%-75% fewer days in cases of inflammatory and post-operative pain. Cytogel’s funding will support Phase 2 clinical trials and expanding studies toward additional indications where the company’s platform technology may offer a safer, more effective path forward for millions living with pain. The U.S. Trademark Certificate of Registration has been issued for CYT-1010 ® . Cytogel also holds a robust portfolio of issued patents and patent applications covering multiple compositions and uses. Cytogel extends appreciation to its Board of Directors for their leadership and commitment: C. Dean Maglaris Chairman & CEO, Jerry Leamon, Frederick Telling, PhD, Eric Lang, MD, Mike Ullmann, Steven G. Chrust, Cassandra Klimp as well as luminaries across the medical, scientific, and advocacy communities who serve on Cytogel’s Advisory Board . About Cytogel Pharma Cytogel Pharma, LLC is a clinical-stage biopharmaceutical startup developing first-in-class drug candidates from the novel endomorphin family of molecules that target key pain pathways. The company’s groundbreaking approach offers a new mechanism of action distinct from traditional opioids, with the goal of providing potent, safe, and non-addictive pain relief for patients worldwide. Disclosure Notice CYT-1010 is an investigational new drug and has not been approved by the FDA or any regulatory body for marketing or for clinical treatment of humans or animals. This release contains forward-looking information about CYT-1010 and a potential new indication for the treatment of patients with moderate to severe post-operative pain via IV administration. The realization of any potential benefits involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Kimberly Weinrick Cytogel Pharma +1 917-224-5335 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Phase 1Clinical Result

30 Oct 2025

·www.einpresswire.com

GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform

GNQ Insilico's Quantum-enhanced and AI-powered Platform to Accelerate Development of MindLab's Novel Pain Management Therapy PLEASANTON, CA, UNITED STATES, October 30, 2025 / EINPresswire.com / -- GNQ Insilico Inc., a pioneer in quantum-enhanced AI drug development, is pleased to announce a strategic partnership with MindLab, LLC to deploy its newly launched Drug Assessment Platform (DAP) to accelerate the development of MLB-001, MindLab’s lead therapeutic candidate designed to transform the treatment of acute pain and rare-disease conditions. The partnership represents the first major commercial engagement for GNQ's recently launched DAP platform and underscores the growing demand for AI-driven modeling solutions that can optimize dosing, predict efficacy and safety outcomes, and strengthen regulatory readiness. MindLab took the first place prize at the RESI Boston Conference held this June, standing out among many promising early-stage life science companies. MindLab will leverage GNQ’s advanced digital-twin technology and AI-driven modeling capabilities to optimize dosing strategies, inform clinical trial design, and strengthen regulatory readiness for the next phase of MindLab’s development. The collaboration will generate predictive modeling of efficacy, safety, and abuse liability—including the euphoria-driven drug misuse potential. MindLab’s proprietary next-generation pain therapeutic is designed to deliver morphine-level analgesia with approximately a 50% lower opioid dose and a longer duration of action, while reducing the euphoria that drives drug abuse and addiction. TRANSFORMING DRUG DEVELOPMENT THROUGH QUANTUM INFUSED CAUSAL AI GNQ's Drug Assessment Platform combines artificial intelligence, quantum computing principles, and sophisticated biological modeling to create digital twins that simulate drug behavior across diverse patient populations. For MindLab's MLB-001 program, this technology will provide critical insights to: • Accelerate Development Timelines by reducing preclinical testing requirements through predictive modeling • Enhance Safety Profiles through early identification of potential safety signals before clinical trials • Optimize Clinical Trial Design with informed patient selection and dosing strategies • Support Regulatory Strategy by providing FDA-aligned quantitative predictions for efficacy versus respiratory depression risk, long-term efficacy, maintenance and physical dependence assessment The platform's ability to model complex drug interactions and predict individual patient responses addresses a critical need in developing controlled substances, where regulatory scrutiny and safety concerns demand unprecedented precision. STRATEGIC ADVANTAGES FROM NOVEL PAIN THERAPIES The partnership positions MindLab to leverage several key advantages: Regulatory Differentiation: The FDA increasingly favors precision medicine approaches for controlled substances. GNQ's personalized risk assessment modeling could support differentiated labeling and enhance approval prospects through patient-specific stratification strategies. Commercial Value Creation: Beyond development acceleration, the insights generated will enable companion diagnostics for patient selection, risk management tools for prescribers, and differentiated market positioning versus standard opioid therapies. Clinical Optimization: Real-time safety monitoring algorithms and adaptive dosing recommendations will maximize the probability of Phase 1 and Phase 2 trial success while minimizing patient risk. INDUSTRY LEADERSHIP PERSPECTIVES "MindLab's decision to adopt our Drug Assessment Platform validates our vision of transforming drug development through quantum enhancement causal inference" said Sudhir Saxena, Chief Technology Officer of GNQ Insilico. "The opioid crisis demands innovation not just in molecular design, but in how we predict and optimize therapeutic outcomes across diverse patient populations. Our digital twin technology will provide MindLab with unprecedented visibility into MLB-001's therapeutic window, allowing them to design safer, more effective pain management solutions with confidence. This partnership demonstrates how AI and quantum-enhanced modeling can compress development timelines while simultaneously improving patient safety outcomes." "Our partnership with GNQ Insilico represents a powerful convergence of neuroscience and AI" said Larry Raoul James, JD, MBA, Founder and CEO of MindLab. “By integrating predictive modeling with our preclinical data, we’re advancing a smarter, faster path to clinical validation and, ultimately, providing new options for patients who live with pain every day.” ABOUT MINDLAB PHARMA, LLC The company is a pharmaceutical development firm focused on creating next-generation pain management therapies that meet the urgent need for effective analgesia with improved safety and reduced abuse potential in acute and rare-disease pain conditions. The company’s lead program, MLB-001, represents a novel approach to opioid therapy through precision combination pharmacology, designed to deliver morphine-level pain relief at approximately 50% lower opioid dose with a longer duration of action and reduced euphoria-driven misuse potential. MindLab is headquartered in New York City, NY. For more information, visit www.mindlabpharma.com or contact info@mindlabpharma.com ABOUT GNQ INSILICO INC. The company is a California-based TechBio firm pioneering the integration of artificial intelligence, quantum computing, and advanced biological modeling for drug development. The company's Drug Assessment Platform (DAP) leverages digital twin technology to predict drug efficacy, safety, and patient response with unprecedented accuracy, enabling pharmaceutical companies to accelerate development timelines, reduce costs, and improve clinical outcomes. GNQ Insilico is headquartered in Pleasanton, CA. For more information, visit www.gnq.ai Rehan Huda GNQ Insilico Inc. info@gnq.ai Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2

15 Jul 2025

·www.einpresswire.com

Diversified Botanics Applauds FDA’s Decisive Action Against Synthetic 7-OH Swift Federal Enforcement Protects Consumers

Removing synthetic 7-OH from commerce is a lifesaving step..."” — Ryan Niddel, CEO of Diversified Botanics SALT LAKE CITY , UT, UNITED STATES, July 15, 2025 / EINPresswire.com / -- Diversified Botanics (DB) today commended the U.S. Food and Drug Administration (FDA) for its rapid and targeted enforcement actions against manufacturers and distributors of synthesized 7-Hydroxymitragynine (7-OH), an unapproved, laboratory-produced opioid reported to be 10–40 times more potent than morphine. “Removing synthetic 7-OH from commerce is a lifesaving step,” said Ryan Niddel, CEO of Diversified Botanics. “The FDA’s team—led by Marty McCary and the dedicated scientists, investigators, and attorneys across CDER and CFSAN—demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.” Lawmakers Led the Charge DB extends special gratitude to Congressman Jack Bergman (MI-01) and Senator Roger Marshall, M.D. (KS), whose early 2025 letters warned FDA leadership that products containing synthetic 7-OH posed an imminent threat to public health. Their foresight accelerated today’s enforcement. Senator Harris likewise merits recognition for championing complementary state-level protections. Separating Science from Pseudoscience Contrary to online misinformation, 7-OH is not equivalent to natural kratom. Natural kratom leaf (Mitragyna speciosa) contains a broad spectrum of at least 40 indole and oxindole alkaloids. ISO-17025 laboratory analyses on over 600,000 kg of raw leaf confirm typical alkaloid ratios. Mitragynine typically comprises approximately 60% (0.8–1.4% of dried leaf), functioning as a partial μ-opioid and adrenergic agent. Paynantheine accounts for around 11% (0.15–0.30% of dried leaf), acting as a 5-HT2A antagonist. Speciogynine represents about 8% (0.10–0.25% of dried leaf) and serves as a smooth-muscle relaxant. Speciociliatine, roughly 6% (0.07–0.18% of dried leaf), functions as a weak μ-opioid partial agonist. Naturally occurring 7-Hydroxymitragynine constitutes less than or equal to 1% (approximately 120 ppm, ≤0.0002% of dried leaf), as an oxidative metabolite of mitragynine. Proposed Kratom Consumer Protection & Safety Acts limit 7-OH to ≤1% of total alkaloids, reflecting these empirical ranges and ensuring a pharmacologically balanced profile. Dr. Robert Redfield, former CDC Director, stated: “The FDA’s expeditious enforcement against synthetic 7-OH exemplifies data-first public health stewardship. It protects consumers while preserving rigorous scientific evaluations of natural kratom.” Looking Ahead Diversified Botanics reiterates its full support for the FDA’s mission and calls on all stakeholders—manufacturers, retailers, and policymakers—to adopt the standards embedded in the Kratom Consumer Protection & Safety Act nationwide. About Diversified BotanicsDiversified Botanics is an innovative industry leader in botanical wellness, committed to producing safe, effective, and natural products. The company maintains transparent, rigorous scientific standards, offering consumers full visibility into the farm-to-table lifecycle of its products through advanced QR code tracking. Diversified Botanics collaborates closely with regulatory and scientific communities, consistently prioritizing consumer health and safety. Christine Haas Christine Haas Media +1 512-751-1592 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Morphine Sulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Morphine Sulfate	N02AA01	DB00295

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	United States	Hikma Pharmaceuticals USA, Inc.	17 Mar 2008
Acute Pain	United States	Hikma Pharmaceuticals International Ltd.	17 Mar 2008
Cancer Pain	Japan	Shionogi Pharma Co., Ltd.	01 Jan 1989
Pain	United States	Purdue Pharma LP	29 May 1987
Chronic Pain	United States	Hikma Pharmaceuticals USA, Inc.	18 Sep 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Opioid-Related Disorders	Phase 3	Canada	Mayne Pharma International Pty Ltd.	06 Dec 2019
Osteoarthritis, Knee	Phase 3	United States	Pfizer Inc.	01 Dec 2006
Pain, Postoperative	Phase 3	United States	Javelin Pharmaceuticals, Inc.	01 May 2006
Neoplasms	Phase 2	Lithuania	Egalet Ltd.	01 Aug 2007
Neoplasms	Phase 2	Poland	Egalet Ltd.	01 Aug 2007
Hallux Valgus	Phase 2	-	Javelin Pharmaceuticals, Inc.	01 Jan 2005
Toothache	Phase 2	-	Javelin Pharmaceuticals, Inc.	01 Sep 2001
Arthralgia	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	-
Neuralgia	Phase 2	China	Hebei Aoxing Group Pharmaceutical Co. Ltd.	-
Anesthesia	Phase 1	-	Pfizer Inc.	01 Aug 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03726268 (OSPREy, CTgov)	Phase 4	Pain, Postoperative	907	Methadone (Short-stay, IV Methadone)	dnbqjvmpdz(rvavzjdfpy) = ztlbssuoft cfibpztjgu (ysywopmcsg, 15.50) View more	-	19 Nov 2025
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	dnbqjvmpdz(rvavzjdfpy) = dtoklvxjjv cfibpztjgu (ysywopmcsg, 11.60) View more
NCT05069012 (CTgov)	Phase 4	Pain, Postoperative	72	Morphine Sulfate (50 Micrograms)	uehzjeotvo(afymhoveje) = klaaejwkfg cvykyzymyb (lhumsmdzxy, psdmwqofkj - gtcyrhsjis) View more	-	13 Nov 2025
				Morphine Sulfate (150 Micrograms)	uehzjeotvo(afymhoveje) = kpprbsauzr cvykyzymyb (lhumsmdzxy, exvpykufus - toxnyqwbkv) View more
NCT06192589 (CTgov)	Phase 1	Chemical and Drug Induced Liver Injury \| Medication interactions	241	cannabidiol (Cannabidiol (Part 1))	qsafcebbvy = dzuwadrjpi rzgyaiupef (iqawfjokru, pfygmmjvgh - hwsafnmsuf) View more	-	31 Jul 2025
				Placebo (Placebo (Part 1))	qsafcebbvy = hmzrvfiwnq rzgyaiupef (iqawfjokru, bleoikgiaw - spthjmtufi) View more
NCT05017246 (CTgov)	Phase 2	Uterine Fibroids	110	Bupivacaine (Epidural Bupivacaine With Hydromorphone Patient-controlled Anesthesia (EPCA))	svbyqgxjje(xjdcdevmvb) = hhjnxbxldi yblvnivhdt (vwolaoldbm, 106.1) View more	-	31 Jul 2025
				Lidocaine+Morphine (Intrathecal Morphine With Intraoperative Lidocaine Infusion)	svbyqgxjje(xjdcdevmvb) = mdgkzlvehy yblvnivhdt (vwolaoldbm, 89.8) View more
Pubmed \| BJS Open	Phase 4	Pain, Postoperative	186	paracetamol+Morphine+nefopam (Intravenous analgesia alone)	rpufveuvys(lghdebxpiz): Difference (Mean) = 0.57 (95.0% CI, 0.21 - 0.93), P-Value = 0.002 View more	Positive	01 Jul 2025
				Intrathecal morphine (ITM)paracetamol+Morphine+nefopam (Intrathecal morphine (ITM)+ Intravenous analgesia)
NCT02720822 (Pubmed \| J Pain Symptom Manage)	Phase 3	Dyspnea	156	Morphine	pclpgjbusx(ckjpivnlfu) = duzaxcvjgr jiekikalll (awceyidowr )	Positive	01 Jun 2025
				Placebo	pclpgjbusx(ckjpivnlfu) = jamrylvlmz jiekikalll (awceyidowr )
NCT03431285 (CTgov)	Not Applicable	Vaso-occlusive crisis \| Pain \| Anemia, Sickle Cell	278	standard IV hydration+Morphine (Morphine Group)	odvrzgchmu(ldefigaaxr) = npxeiltpyl ndalcfiohs (jkkhxtmfts, 1.90) View more	-	28 May 2025
				standard IV hydration+Ketamine Group (Ketamine Group)	odvrzgchmu(ldefigaaxr) = mhnttqqejw ndalcfiohs (jkkhxtmfts, 2.13) View more
NCT03396588 (No-POPPY, CTgov)	Phase 3	Neonatal Abstinence Syndrome \| Brain Injuries	120	Clonidine (Clonidine)	xpsprxvtcm(czytrocjrm) = cntrnfullj afziixeckr (qilqpiynfi, yqerhfozyb - oowfolrpkx) View more	-	23 May 2025
				Morphine (Morphine)	xpsprxvtcm(czytrocjrm) = gzsyycivlu afziixeckr (qilqpiynfi, qvfovilqch - towltufyah) View more
NCT05506930 (CTgov)	Phase 4	Analgesia	14	Intrathecal Morphine (Intrathecal Morphine)	wfdkmbprdf(ubfiqndedq) = ibnyggehod tycxxmpjfx (acfybmzmnf, 0.8) View more	-	15 Apr 2025
				Quadratus lumborum block (Quadratus Lumborum Block)	wfdkmbprdf(ubfiqndedq) = kyyfaaaaca tycxxmpjfx (acfybmzmnf, 1.4) View more
NCT04214834 (CTgov)	Phase 3	Neonatal Abstinence Syndrome	189	methadone+morphine (Rapid Wean)	gjgfvmvpjf(yhfttkusjo) = gddhzrohor jlcofnffac (zmraqvhmzs, 6.3) View more	-	13 Mar 2025
				methadone+morphine (Slow Wean)	gjgfvmvpjf(yhfttkusjo) = wavurdgjnn jlcofnffac (zmraqvhmzs, 6.1) View more